Two studies presented at the American Academy of Neurology’s 66th Annual Meeting, 2014, may offer hope to people with migraines. The two phase II drugs (ALD403 and LY2951742) significantly reduced the number of migraine days per month. Read more.
Δ
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
Notifications
